Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in RBC Membranopathies and CDAII (SATISFY-CA)
NCT07055243Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Oct 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitapivat in erythrocyte membrane disorder, Congenital Dyserythropoietic Anemia Type 2, sponsored by University Health Network. Started Oct 2025; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
erythrocyte membrane disorderCongenital Dyserythropoietic Anemia Type 2
Beyond the preview
Go deeper on NCT07055243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055243.